Cyramza

Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-Based Therapy (RANGE): Overall Survival and Updated Results of a Randomised, Double-Blind, Phase 3 Trial Bookmark

Research paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes: 

A drug called Cyramza improves progession-free survival (PFS) but not overall survival (OS) of patients with advanced bladder cancer in a phase lll clinical trial.

Go to full paper published in The Lancet.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.